Skip to main content
Shandong Sito Bio-technology Co., Ltd. logo

Shandong Sito Bio-technology Co., Ltd. — Investor Relations & Filings

Ticker · 300583 ISIN · CNE100002F36 LEI · 836800ENMRCW06CD2U25 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,388 across all filing types
Latest filing 2026-06-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300583

About Shandong Sito Bio-technology Co., Ltd.

https://www.sitobiotech.com

Shandong Sito Bio-technology Co., Ltd. specializes in the research, development, and production of steroid hormone intermediates and active pharmaceutical ingredients (APIs). The company utilizes biological fermentation technology to transform phytosterols into critical precursors, including 4-AD, ADD, and 9-OH-AD. These materials are fundamental components for the synthesis of glucocorticoids, sex hormones, and progestogens. By integrating microbial strain engineering with large-scale industrial fermentation, the company provides high-purity raw materials for global drug manufacturing. Its operations emphasize green chemistry and sustainable production methods, maintaining a comprehensive supply chain that spans from raw material processing to the delivery of specialized chemical intermediates.

Recent filings

Filing Released Lang Actions
关于为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 85% confidence The document is an official progress announcement by Shandong Qito Bio (证券简称：赛托生物) regarding the provision of a guarantee to its wholly-owned subsidiary for a bank credit facility. It details the guarantee amount, term, contracting parties, and the subsidiary’s audited financials. This is a financing-related disclosure (guarantee on credit facilities) rather than a full financial report or board change. Under the classification scheme, such updates on financing activities (including guarantees for loans) fall under Capital/Financing Update (CAP), not a report publication or regulatory catch-all.
2026-06-05 Chinese
关于回购公司股份比例达到1%暨回购进展的公告
Transaction in Own Shares Classification · 90% confidence The document is a regulatory announcement by Shandong Saituo Biotechnology Co., Ltd. regarding the progress of its ongoing share repurchase plan, including specific repurchase quantities, prices, and percentages of total share capital. This clearly matches the definition of a "Transaction in Own Shares" (POS) filing, which covers reports of a company buying back its own shares.
2026-06-03 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 90% confidence The document is an announcement by the company and its board disclosing the progress of the first share repurchase under an approved buyback plan, including number of shares, prices, and compliance details. This falls squarely under transaction in own shares (share buyback) filings.
2026-05-28 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is a formal announcement of the resolutions and voting results of the company’s 2025 annual general shareholders’ meeting, detailing attendance, each proposal voted on, the vote counts (for/against/abstain), and concluding that the votes are valid and effective. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements.
2026-05-22 Chinese
国浩律师（杭州）事务所关于山东赛托生物科技股份有限公司2025年年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter from an external law firm on the 2025 annual shareholders’ meeting of Shandong Saituo Biotechnology Co., Ltd. It includes detailed vote counts and percentages for each resolution, constituting the official declaration of voting results at the AGM. This matches the Definition for “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-22 Chinese
董事、高级管理人员薪酬管理制度（2026年5月）
Remuneration Information Classification · 91% confidence The document is titled “董事、高级管理人员薪酬管理制度” (Board and Senior Management Remuneration Management System) and outlines detailed policies on compensation structure, levels, adjustments, committees, and recovery for directors and senior executives. It does not contain financial statements or report publication language, but rather an internal governance policy on executive pay. This aligns with the definition of Remuneration Information (DEF 14A).
2026-05-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.